Demeclocycline
| Evidence Level: L5 | Predicted Indications: 3 |
Table of Contents
- Demeclocycline
- Pharmacist Assessment Report
- Demeclocycline: Tetracycline-class antibiotic → chronic ethmoidal sinusitis
- One-Sentence Summary
- Quick Overview
- Why is This Prediction Reasonable?
- Clinical Trial Evidence
- Literature Evidence
- India Market Information
- Safety Considerations
- Conclusion and Next Steps
- Disclaimer
Demeclocycline: Tetracycline-class antibiotic → chronic ethmoidal sinusitis
One-Sentence Summary
Demeclocycline is a tetracycline-class antibiotic. The TxGNN model predicts it may be effective for chronic ethmoidal sinusitis, with a score of 0.9914. No clinical trials and no publications currently support this direction, so the prediction rests on the model alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | chronic ethmoidal sinusitis |
| TxGNN Prediction Score | 0.9914 |
| Evidence Level | L5 |
| India Market Status | Listed in a compiled Indian medicine price dataset (2 of 2) – CDSCO approval status is not included in this data |
| Number of Listed Products | 2 (valid: 2) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data for demeclocycline is not available in the data compiled for this report. Based on general knowledge, demeclocycline belongs to the tetracycline class of antibiotics, which act against a broad range of bacteria. Members of this class are also reported to have anti-inflammatory and matrix metalloproteinase-inhibiting properties.
Chronic ethmoidal sinusitis is a long-standing inflammation of the ethmoid sinuses, often with bacterial involvement. In theory, antibacterial and immunomodulatory activity could be relevant to this condition. A closely related condition, chronic rhinosinusitis, is also among the model’s predictions.
These links are plausible but are not supported by any trial or publication in the compiled data. The score of 0.9914 is a computational output, not clinical evidence.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
India Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 124393 | Ledermycin 150mg Tablet | Strip of 10 tablets | Not recorded |
| 122118 | Ledermycin 300mg Tablet | Strip of 10 tablets | Not recorded |
Both products are single-ingredient oral tablets from Pfizer Ltd, and both licences are currently valid.
Safety Considerations
- Drug Interactions: 154 interactions were identified. The listed examples include:
- Major: Vitamin A.
- Moderate: Amoxicillin, balsalazide, calcium salts (phosphate, acetate), magnesium salts (oxide, sulfate, chloride), zinc salts (sulfate, acetate), potassium citrate, and several insulin products (aspart, degludec, detemir, glargine, glulisine, human).
- Minor: Mannitol.
For warnings and contraindications, please refer to the package insert.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction is supported only by a model score, with no clinical trials or publications on chronic ethmoidal sinusitis. Package-insert safety data and mechanism of action data are also missing, so a further decision is premature.
To proceed, the following is needed:
- A literature and trial search directly on demeclocycline in chronic ethmoidal sinusitis and chronic rhinosinusitis
- Mechanism of action data for demeclocycline
- Package insert warnings and contraindications for the Indian products
- A review of interaction risks, especially with polyvalent cations (calcium, magnesium, zinc), vitamin A and insulin
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.